NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-03. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Positive Phase 1/2 peer-reviewed clinical data lowers regulatory approval risk for RVMD oncology pipeline.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factThe New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE) in pretreated RAS-mutant non-small cell lung cancer. |
| What else was confirmed? | Reported factThe trial demonstrated a 42% objective response rate in docetaxel-treated patients. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for RVMD yet — this is the next research task. |
| What would change the assessment? | UnknownRVMD market reaction to NEJM publication — Trading volume and price action at regular market open. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · The New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE) in pretreated RAS-mutant non-small cell lung cancer.
- · The trial demonstrated a 42% objective response rate in docetaxel-treated patients.
- · Median overall survival reached 16.0 months in the evaluated cohort.
Public research record
Research framework · page evidenceCompleted event assessment
clinical pipeline de-risking boosting biotechnology valuation
| Type | Claim | Scope |
|---|---|---|
| Assumption | The New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE) in pretreated RAS-mutant non-small cell lung cancer. | 2026-09-03 |
| Interpretation | clinical pipeline de-risking boosting biotechnology valuation | RVMD |
Countercase, invalidators, and sources
Pivotal Phase 3 study initiation confirms Phase 1/2 efficacy, accelerating accelerated approval timeline.
- · RVMD market reaction to NEJM publication — Trading volume and price action at regular market open.
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer · 2026-09-02
What remains unresolved
- Base path
- RVMD advances daraxonrasib through registration trials with regulatory engagement.
- Adverse path
- Confirmatory trials show response decay or adverse safety signals in broader patient cohorts.
- Supportive path
- Pivotal Phase 3 study initiation confirms Phase 1/2 efficacy, accelerating accelerated approval timeline.
- · RVMD market reaction to NEJM publication — Trading volume and price action at regular market open.today
Evidence
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer2026-09-02
“Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a doce”
Supports: NEJM published Phase 1/2 trial data for daraxonrasib with 42% ORR and 16.0 months median OS in pretreated RAS-mutant NSCLC.